MICROPORT (00853) announced the first half 2025 financial results for Shanghai Microport Endovascular Medtech(Group)Co.,Ltd., showing revenue of approximately RMB 714 million, representing a year-over-year decrease of 9.24%. Net profit attributable to Shanghai Microport Endovascular Medtech(Group)Co.,Ltd. shareholders reached approximately RMB 315 million, down 22.03% compared to the same period last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.